EW
Edwards Lifesciences·NYSE
--
--(--)
--
--(--)
EW fundamentals
Edwards Lifesciences (EW) released its earnings on Feb 10, 2026: revenue was 1.57B (YoY +13.26%), beat estimates; EPS was 0.58 (YoY -1.69%), missed estimates.
Revenue / YoY
1.57B
+13.26%
EPS / YoY
0.58
-1.69%
Report date
Feb 10, 2026
EW Earnings Call Summary for Q4,2025
- Record Growth: 11.6% Q4 and 10.7% full-year revenue growth, driven by TAVR (10.6% YoY), TMTT (40% Q4), and Surgical ($1B+ annual sales).
- TAVR Leadership: SAPIEN platform gains share amid competitor exit, with 7-year PARTNER III and 10-year PARTNER II data reinforcing long-term durability. Q4 procedural growth in high single digits globally.
- TMTT Expansion: $500M+ annual TMTT sales, with PASCAL, EVOQUE, and SAPIEN M3 driving mitral/tricuspid repair/replacement growth. Targeting $2B+ by 2030.
- Financial Confidence: 2026 guidance reaffirmed (8-10% sales growth, $2.90-3.05 EPS), with 78-79% gross margin and 16-19% tax rate.
- Strategic Initiatives: $112M Q4 SG&A investment in patient access, LAA launch late 2026, and PROGRESS trial results expected at TCT.
EPS
Actual | 0.5033 | 0.34 | 0.51 | 0.5 | 0.54 | 0.64 | 0.54 | 0.51 | 0.6 | 0.63 | 0.61 | 0.64 | 0.62 | 0.66 | 0.59 | 0.64 | 0.66 | 0.7 | 0.67 | 0.59 | 0.64 | 0.67 | 0.67 | 0.58 | |||||||||||||||
Forecast | 0.4386 | 0.1867 | 0.4429 | 0.5301 | 0.4727 | 0.5548 | 0.5326 | 0.5483 | 0.5712 | 0.6404 | 0.6213 | 0.616 | 0.6084 | 0.6478 | 0.5931 | 0.6373 | 0.6429 | 0.6943 | 0.6646 | 0.5507 | 0.5965 | 0.6237 | 0.5961 | 0.6194 | |||||||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +14.75% | +82.11% | +15.15% | -5.68% | +14.24% | +15.36% | +1.39% | -6.99% | +5.04% | -1.62% | -1.82% | +3.90% | +1.91% | +1.88% | -0.52% | +0.42% | +2.66% | +0.82% | +0.81% | +7.14% | +7.29% | +7.42% | +12.40% | -6.36% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.13B | 925.00M | 1.14B | 1.19B | 1.22B | 1.38B | 1.31B | 1.33B | 1.34B | 1.37B | 1.32B | 1.35B | 1.46B | 1.53B | 1.48B | 1.53B | 1.60B | 1.63B | 1.35B | 1.39B | 1.41B | 1.53B | 1.55B | 1.57B |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.08B | 793.92M | 1.08B | 1.18B | 1.16B | 1.28B | 1.32B | 1.35B | 1.31B | 1.40B | 1.33B | 1.33B | 1.39B | 1.51B | 1.48B | 1.50B | 1.57B | 1.65B | 1.54B | 1.36B | 1.40B | 1.49B | 1.50B | 1.55B |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +4.16% | +16.51% | +5.59% | +0.61% | +4.68% | +7.26% | -0.89% | -1.72% | +2.37% | -1.60% | -1.12% | +1.09% | +4.67% | +1.66% | +0.06% | +2.49% | +1.80% | -1.27% | -12.31% | +1.98% | +0.87% | +2.97% | +3.69% | +1.48% |
Earnings Call
You can ask Aime
What were the key takeaways from Edwards Lifesciences’s earnings call?What is the revenue and EPS growth rate for Edwards Lifesciences year over year?What is Edwards Lifesciences's latest dividend and current dividend yield?What is Edwards Lifesciences's gross profit margin?What guidance did Edwards Lifesciences's management provide for the next earnings period?What is the market's earnings forecast for Edwards Lifesciences next quarter?What does Edwards Lifesciences do and what are its main business segments?What factors drove the changes in Edwards Lifesciences's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
